Long-term effects of BRAF inhibitors in melanoma treatment: Friend or foe?

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 5, 2014, Pages 589-592

  Sloot, Sarah ^a,b   Fedorenko, Inna V ^a   Smalley, Keiran Sm ^a,c   Gibney, Geoffrey T ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

BRAF; Dabrafenib; MAPK; Melanoma; Paradoxical oncogenesis; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; TRAMETINIB; VEMURAFENIB;

CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CUTANEOUS MELANOMA; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM METASTASIS; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84896268836     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.881471     Document Type: Review

References (15)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
2. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
4. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
5. Kim K, Ribas A, Chmielowski B, et al. Long term safety and efficacy of vemurafenib in the treatment of BRAFV600-mutant advanced melanoma (BRIM-2 study update). Pigment Cell Melanoma Res 2012;25:866
6. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
7. Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis-the longterm effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390-9
8. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15
9. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-18
10. Filitis DC, Mahalingam M. Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset. Am J Clin Dermatol 2013;14:461-71
11. Chapman P, Metz D, Sepulveda A, et al. Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res 2012;25:847
12. Andrews MC, Behren A, Chionh F, et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/ 2 inhibition. J Clin Oncol 2013;31(35):e448-51
13. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703
14. Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective Pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res 2013;73:7043-55
15. Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50